Clinical Trial: Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.

U.S., Nov. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07909005) titled 'Long Term Safety Study in Patients With HLH/MAS in Still's Disease Exposed to Gamifant.' on Oct. 14.

Brief Summary: This study aims to evaluate safety information in patients with HLH/MAS in Still's disease exposed to Gamifant.

Study Start Date: Dec., 2026

Study Type: OBSERVATIONAL

Condition: Hemophagocytic Lymphohistiocytosis (HLH) Macrophage Activation Syndrome (MAS) Still Disease

Intervention: OTHER: Local laboratory testing

Protocol-mandated assessments include specified laboratory testing at baseline and during the initial 12 months of follow-up (Week 1, Week 2, Month 1, Month 3, Month 6, Month 12): complete blood counts,...